FIELD: chemico-pharmaceutical industry.
SUBSTANCE: the present innovation deals with applying receptor NK-1 antagonist, not obligatory in combination with magnesium salt, for treating and/or preventing craniocerebral and spinal trauma or nervous tissue lesion, where receptor NK-1 antagonist is being a compound of general formula 
, where R, R1, R2, R2', R3, R4 have values mentioned in the description of the present innovation, its pharmaceutically acceptable acid-additive salts, either separately or in combination with magnesium salt. The example is the application of 2-(3.5-bis-trifluoromethylphenyl)-N-methyl-N-(6-morpholine-4-yl-4-ortho-tolylpyridine-3-yl)isobutyramide.
EFFECT: higher efficiency of therapy.
8 cl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF 4-PHENYLPYRIDINE N-OXIDES, MEDICINAL AGENT COMPRISING THEREOF | 2001 |
|
RU2266284C2 |
| DERIVATIVES OF 3-PHENYLPYRIDINE AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2000 |
|
RU2236402C2 |
| DERIVATIVES OF BENZENE OR PYRIDINE AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2000 |
|
RU2238264C2 |
| DERIVATIVES OF 4-PHENYLPYRIDINE AND MEDICINAL AGENT BASED ON THEREOF | 2001 |
|
RU2277087C2 |
| DERIVATIVES OF 4-PHENYLPYRIDINE AND MEDICINAL AGENT | 2001 |
|
RU2276139C2 |
| DERIVATIVES OF 4-PHENYLPYRIMIDINE AND PHARMACEUTICAL COMPOSITION | 2000 |
|
RU2243221C2 |
| NK1/NK3 DOUBLE AGONISTS FOR TREATING SCHIZOPHRENIA | 2004 |
|
RU2347777C2 |
| DERIVATIVES OF PYRIMIDINE AND PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2284997C2 |
| DERIVATIVES OF DIPHENYL AND MEDICINAL AGENT | 2000 |
|
RU2238266C2 |
| NEW DOSAGE FORM | 2006 |
|
RU2431473C2 |
